Business Wire

Dubai World Challenge for Self-Driving Transport Winners Announced for Prizes Worth USD 5.1 Million

15.10.2019 23:12:00 EEST | Business Wire | Press release

Share

Dubai World Congress for Self-Driving Transport; organised by Roads and Transport Authority (RTA) Dubai on 15th and 16th October 2019 has attracted more than 700 technology leaders and innovators as well as 3000 visitors of the accompanying exhibition. The congress focuses on cutting-edge technologies, besides discussing and developing a general legislative structure for autonomous transport.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191015006107/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Winners of the Dubai World Self-Driving Transport Challenge (Photo: AETOSWire)

The event is part of RTA’s efforts in support of the strategy unleashed by HH Sheikh Mohammed bin Rashid Al Maktoum, Vice-President and Prime Minister of the UAE and Ruler of Dubai, to make 25% of all trips in Dubai smart and driverless by 2030. The congress attracted 80 international experts, including five keynote speakers, who will be taking part in 40 lectures and 39 technical workshops.

The congress is shaping into an all-inclusive global platform for self-driving transport that brings together top experts, policymakers, technology developers, researchers and academia. The event aims to highlight the leading role of Dubai Government in self-driving transport and accelerate the drive to achieve the targets of Dubai Autonomous Transportation Strategy through attracting experts and technologies of self-driving transport to Dubai. The event also aims to raise public awareness about the latest technologies and future trends of transportation as well as identifying the potential impacts on investments and different transport strategies.

Dubai Challenge

Dubai World Challenge for Self-Driving Transport, which carries prize money of US$5.1 million (about 19m Dirhams) attracted 65 entities from 20 countries, 15 of them qualified for the finals. The challenge focused on the first and last-mile challenge of mobility journeys.

Five leading companies, three start-ups and seven local and foreign universities qualified for the finals. Qualifying vehicles were subjected to different scenarios and tests on a dedicated track tailor-made for testing such vehicles at the Dubai Silicon Oasis.

Tests carried included stopping at bus stops, forced stop, overtaking a stopping vehicle, overtaking a bike, and dealing with various traffic scenarios such as signals, pedestrian crossing, road works, and sand on road. Tests also covered negotiating a roundabout, handling of humps, rains and high-speed turns.

Nominees for the challenge were qualified on certain parameters including the status, credibility, vision, skills and relevant experience of the entity. They were then subjected to several tests in various categories to assess their performance under six key standards and 18 subsidiary standards. Key standards covered the operation plan, tolerance and reliability, sustainability and energy, customer experience, safety and security, and dealing with road users.

Awards

The list of winners was delivered by autonomous delivery bot Roxo developed by FedEx Express in a fitting move with Dubai being selected as the first city outside the USA to host the test of this personal delivery bot. French companies swept the prizes of leading companies amounting to USD 3 million. Gaussin won the sustainability and energy award, Navya won the durability and reliability award as well as the customers' experience award.

In the start-ups category the first USD 1 million went to Sensible 4 from Finland, while the runner-up was iAuto from Taiwan who bagged USD 500,000 while UAE-based Derq Company finished third.

Amongst the international universities, the winner was Freie Universität Berlin which received USD 200,000; while Carlos III de Madrid University won second place with USD 100,000 and the Australian University UTS came third. In the local universities, Dubai University finished first with USD 200,000; UAE University came second bagging USD 100,000 and Al Ain University was third.

The Dubai World Challenge for Self-Driving Transport comprised several phases. In February 2018 the challenge was announced, and in October 2018 qualifiers for Phase II were announced. In February 2019, Phase II started and in March tests started at Dubai Silicon Oasis. From April to June this year, a team made overseas visits to Taiwan, Finland, Australia, Germany and Spain to assess start-ups and academia. In July qualifiers arrived in Dubai to collect geographical data about test tracks and draw maps, and in August vehicle tests started on the challenge track. Winners were selected according to results achieved in tests.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Roads and Transport Authority (RTA)
Maryam Al Balooshi, Manager, Media Communication
Marketing and Corporate Communication Department
Tel: +97142902699
Email Maryam.HAlblooshi@rta.ae

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye